149 related articles for article (PubMed ID: 2418949)
1. In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.
Webb KS; Liberman SN; Ware JL; Walther PJ
Cancer Immunol Immunother; 1986; 21(2):100-6. PubMed ID: 2418949
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy.
Webb KS; Ware JL; Parks SF; Walther PJ; Paulson DF
Cancer Treat Rep; 1985 Jun; 69(6):663-72. PubMed ID: 4040422
[TBL] [Abstract][Full Text] [Related]
3. Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.
Webb KS; Poulton SH; Liberman SN; Walther PJ
J Urol; 1989 Aug; 142(2 Pt 1):425-32. PubMed ID: 2787412
[TBL] [Abstract][Full Text] [Related]
4. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
5. Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.
Brusa P; Pietribiasi F; Bussolati G; Dosio F; Arione R; Comoglio PM; Prat M; Cattel L
Cancer Immunol Immunother; 1989; 29(3):185-92. PubMed ID: 2659170
[TBL] [Abstract][Full Text] [Related]
6. Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells.
Levin LV; Griffin TW; Childs LR; Davis S; Haagensen DE
Cancer Immunol Immunother; 1987; 24(3):202-6. PubMed ID: 3496151
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
8. Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells.
Vitetta ES; Cushley W; Uhr JW
Proc Natl Acad Sci U S A; 1983 Oct; 80(20):6332-5. PubMed ID: 6578512
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
11. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.
Blakey DC; Skilleter DN; Price RJ; Thorpe PE
Biochim Biophys Acta; 1988 Feb; 968(2):172-8. PubMed ID: 3257705
[TBL] [Abstract][Full Text] [Related]
12. Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates.
Thiesen HJ; Juhl H; Arndt R
Cancer Res; 1987 Jan; 47(2):419-23. PubMed ID: 3539323
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
[TBL] [Abstract][Full Text] [Related]
14. Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies.
Griffin TW; Stocl M; Collins J; Fernandes J; Maher VE
J Immunother (1991); 1992 Jan; 11(1):12-8. PubMed ID: 1734944
[TBL] [Abstract][Full Text] [Related]
15. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
16. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
17. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
18. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
19. Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro.
Recht LD; Griffin TW; Raso V; Salimi AR
Cancer Res; 1990 Oct; 50(20):6696-700. PubMed ID: 2208135
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody-ricin A chain conjugates (immunotoxins): potential therapeutic agents for human colon carcinoma.
Gallagher WJ; Burk MW
J Surg Res; 1986 Feb; 40(2):159-66. PubMed ID: 3945071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]